Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Aging (NIA) |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00239759 |
The goal of MIRAGE is to evaluate the association of genetic and non-genetic risk factors for Alzheimer's Disease.
Condition |
---|
Alzheimer's Disease |
Study Type: | Observational |
Official Title: | Genetic Epidemiological Studies of Apolipoprotein E and Alzheimer's Disease |
Estimated Enrollment: | 2000 |
Study Start Date: | September 2002 |
Study Completion Date: | June 2008 |
For the past 13 years the MIRAGE project has demonstrated that genetic factors play a major role in the development of Alzheimer's Disease (AD) among patients ascertained in clinical settings. This research has also shown that the E4 variant of apolipoprotein E (APOE), is the strongest AD risk factor identified thus far.
The researchers are turning their attention to the growing body of evidence from pathological, epidemiological and genetic studies that risk factors for vascular disease also enhance the risk of AD. However, since most epidemiological studies lack neuroimaging data, it is unclear whether the apparent association between vascular risk factors and AD is brought about by ischemic injury to the brain, acceleration of the primary Alzheimer neurodegenerative process, or some other process.
Some vascular risk factors are more prevalent in African American and Japanese American populations than in Caucasians. This study will build upon earlier work by evaluating the association between APOE, genes involved in vascular function, and other indictors of cerebrovascular health including blood pressure and structural brain imaging (MRI), and susceptibility to AD in these ethnic groups.
In order to carry out this project successfully, a sample of 1000 patients (500 Caucasians, 300 African Americans, 200 Japanese Americans) who meet NINCDS/ADRDA criteria for probable or definite AD from 11 centers in the U.S., Canada and Germany will be recruited. Many patients will be identified from the existing family registries. Family history, medical history, and epidemiological information will be obtained from the AD patient and their first-degree relatives using standardized questionnaire instruments and established protocols. A cognitive screening test will be administered to and blood samples will be collected from the patient's living siblings, spouses and children over the age of 50 years. DNA, plasma and MRI of the brain will be evaluated in patients and siblings.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
NOTE: This trial accepts patients with Probable AD, and their cognitively normal brothers or sisters
Exclusion Criteria:
United States, Alabama | |
University of Alabama | |
Birmingham, Alabama, United States, 35233 | |
United States, Arizona | |
Sun Health Research Institute | |
Sun City, Arizona, United States, 85351 | |
United States, California | |
Rancho Los Amigos National Rehabilitation Center/University of Southern California | |
Downey, California, United States, 90242 | |
University of California, Davis | |
Sacramento, California, United States, 95817 | |
United States, District of Columbia | |
Howard University | |
Washington, District of Columbia, United States, 20060 | |
United States, Florida | |
University of Miami School of Medicine | |
Miami Beach, Florida, United States, 33140 | |
United States, Georgia | |
Morehouse School of Medicine | |
Atlanta, Georgia, United States, 30310 | |
United States, Hawaii | |
Pacific Health Research Institute | |
Honolulu, Hawaii, United States, 96817 | |
United States, Indiana | |
Indiana University School of Medicine | |
Indianapolis, Indiana, United States, 46202 | |
United States, Massachusetts | |
Boston University School of Medicine | |
Boston, Massachusetts, United States, 02118 | |
United States, New York | |
Cornell Medical University | |
New York City, New York, United States, 10021 | |
United States, Ohio | |
Case Western Reserve University | |
Cleveland, Ohio, United States, 44106 | |
Canada, British Columbia | |
University of British Columbia | |
Vancouver, British Columbia, Canada, V6T 2B5 | |
Germany | |
Technical University of Munich | |
Munich, Germany, P-81675 | |
Greece | |
G. Papanicolaou Hospital | |
Exholi Thessaloniki, Greece, S7010 |
Principal Investigator: | Lindsay Farrer, PhD | Chief, Genetics Program, Boston University |
Study ID Numbers: | IA0085, 2R01AG0902911-A2 |
Study First Received: | October 13, 2005 |
Last Updated: | February 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00239759 History of Changes |
Health Authority: | United States: Federal Government |
Epidemiological study |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Neurodegenerative Diseases |
Brain Diseases Dementia Cognition Disorders Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Nervous System Diseases Alzheimer Disease Central Nervous System Diseases |
Neurodegenerative Diseases Tauopathies Brain Diseases Dementia |